Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MDX 2003

Next Previous
Drug Profile

MDX 2003

Alternative Names: MDX-2003

Latest Information Update: 04 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ModeX Therapeutics Inc
  • Class Antibodies; Antineoplastics; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma
  • Preclinical Leukaemia

Most Recent Events

  • 03 Mar 2026 Phase-I/II clinical trials in Lymphoma (Second-line therapy or greater) in Australia (IV, Infusion) (NCT07249905)
  • 06 Dec 2025 Pharmacodynamics and adverse event data from a preclinical trial in Haematological malignancies (B- cell malignancies) presented at the 67th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2025)
  • 25 Nov 2025 ModeX Therapeutics plans a phase I/II trial for Lymphoma (Second line therapy or greater) (IV, Infusion) in March 2026 (NCT07249905)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top